ClinicaliQ Trial Snapshot
- A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies — Recruiting • Phase II • Oncology • NCT07415031.
- Being Tested: Long-term safety, tolerability, and efficacy of adagrasib (a KRAS G12C inhibitor) as continued treatment in patients with solid tumours, predominantly NSCLC, who previously participated in parent clinical trials.
- Patient Eligibility Overview: Participants must be enrolled from active adagrasib parent studies, have demonstrated clinical benefit or stable disease, and be deemed suitable for continued treatment by their clinician; includes patients receiving adagrasib monotherapy or in combination regimens.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is an open-label, solid tumor, continuation, rollover trial which enrolls participants from ongoing BMS parent studies that evaluated adagrasib (MRTX849, BMS-986503) either as monotherapy or in combination with other cancer therapies in patients with non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other advanced solid tumors.
Eligibility Snapshot
- : * Participant is eligible to receive continued study treatment as per the parent study, and/or investigator assessed clinical benefit. * Individuals with assigned female sex at birth (AFSB) must have documented proof that they are not of childbearing potential. IOCBP participants who are sexually active must agree to follow the instructions for method(s) of contraception and included in the ICF.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.